Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Veritone Q2 2026 Earnings Call - Cost Cuts and VDR Pipeline Offset Public Sector Delays
Veritone delivered a mixed Q2 2026 report, posting $24.3 million in revenue with strong sequential growth driven by its Veritone Data Refinery (VDR) and media licensing, though full-year guidance was ...
- Q2 2026 revenue came in at $24.3 million, up 20% sequentially and 5% year-over-year, driven primarily by a 40% quarter-over-quarter surge in combined VDR and licensing services.
- The company executed $11.3 million in annualized cost reductions through headcount cuts and reduced consulting fees, with a target of $15 million to $20 million in total annualized savings by the end of fiscal 2026.
- Full-year 2026 revenue guidance was revised downward to a range of $100 million to $150 million, with the midpoint representing a 17% increase from fiscal 2025, reflecting timing delays in government contracts.
- +7 more takeaways
Nektar Therapeutics Q2 2026 Earnings Call - ZENITH AD Phase III Launches with $1B Cash Runway
Nektar Therapeutics has officially initiated the global ZENITH AD Phase III program for rezpegaldesleukin (REZPEG) in atopic dermatitis, marking a critical pivot from development to registration. The ...
- ZENITH AD Phase III program for atopic dermatitis is now active, with two biologic- and JAK-inhibitor-naïve studies enrolling in July and a treatment-experienced study starting by end of September.
- Top-line data from the atopic dermatitis Phase III studies is expected in mid-2028, with a Biologics License Application (BLA) submission targeted for 2029 if results are positive.
- A single registrational Phase III study for alopecia areata, named ZENITH AA, was finalized following FDA alignment and is scheduled to begin in early 2027.
- +7 more takeaways
Digimarc Q2 2026 Earnings Call - New CEO Pivots to Retail and CPG While ARR Shrinks
Digimarc is undergoing a structural transformation under new CEO Paul Carreiro, who identifies a commercial execution gap as the primary constraint on the company’s proprietary watermarking technology...
- New CEO Paul Carreiro frames the company’s turnaround around fixing a 'commercial execution gap,' arguing that while the technology is differentiated, past leadership failed to convert it into repeatable revenue.
- Digimarc is narrowing its go-to-market focus to two core verticals: Retail and CPG, while transitioning other sectors like pharma and government to a partner-led horizontal model to conserve capital.
- The Retail strategy is anchored by a Secure Gift Card solution, which is live in production at Schnucks (115 stores) and has expanded its pipeline from one retailer at the start of the year to over 31 prospects.
- +9 more takeaways
MDxHealth Q2 2026 Earnings Call - Resolve Wind-Down Complete and Core Urology Business Accelerates
MDxHealth delivered a pivotal second quarter defined by the successful closure of its Resolve UTI business and a sharp rebound in its core prostate cancer diagnostics. Revenue rose 16% year-over-year ...
- Q2 revenue reached $27.2 million, a 16% increase year-over-year and the largest sequential growth in company history at 14%.
- The company completed the wind-down of the Resolve UTI business, closing the Plano, Texas lab and classifying the unit as a discontinued operation.
- A $10.4 million contingent liability to Novitas was eliminated from the corporate structure through the organized cessation of the Delta Laboratories subsidiary.
- +7 more takeaways
Celcuity Q2 2026 Earnings Call - REVTORPYK Approved with $6B Market Opportunity and Late Q3 Launch
Celcuity has secured FDA approval for REVTORPYK (gedatolisib) for HR-positive, HER2-negative advanced breast cancer in patients without a PIK3CA mutation, following a preferred Category 1 recommendati...
- FDA Approval Granted: REVTORPYK was approved on July 14, 2026, for HR-positive, HER2-negative advanced breast cancer in patients without a PIK3CA mutation, following progression on endocrine therapy.
- NCCN Category 1 Recommendation: The NCCN updated guidelines to include both the REVTORPYK triplet and doublet regimens as preferred Category 1 options for second-line treatment in the wild-type population.
- Clinical Efficacy in Mutant Cohort: In the PIK3CA mutant cohort of the VIKTORIA-1 study, gedatolisib demonstrated a median progression-free survival (PFS) of 11.1 months (triplet) and 11.3 months (doublet), compared to 5.6 months for alpelisib, with a hazard ratio of approximately 0.5.
- +7 more takeaways
PetMed Express Q1 2027 Earnings Call - Loss Narrows 82% as White Label Strategy and Real Estate Sale Unlock Capital
PetMed Express delivered a sharp turnaround in profitability during Q1 2027, narrowing its net loss to $6.1 million from $34.2 million a year ago, despite a 19.9% year-over-year drop in revenue. The i...
- Net loss narrowed significantly to $6.1 million ($0.28 diluted loss per share) compared to $34.2 million ($1.65 loss) in Q1 2026, marking a substantial improvement in bottom-line performance.
- Revenue stabilized at $41 million, representing a third consecutive quarter of revenue above the $40 million threshold, though this reflects a 19.9% year-over-year decline primarily driven by reduced prescription medication sales.
- Gross profit margin contracted slightly to 27.6% from 28.1% year-over-year, largely due to lower manufacturer rebates as a percentage of sales, partially offset by reduced freight costs per order.
- +7 more takeaways
KULR Technology Group Q2 2026 Earnings Call - Management Exits Bitcoin Strategy to Focus on Core Battery Operations Amidst Q2 Revenue Miss
KULR Technology Group reported a disappointing second quarter with revenue falling to $2.1 million and recording a gross loss, driven by supply chain bottlenecks, execution constraints, and leadership...
- Q2 2026 revenue was $2.1 million, a significant decline from both the prior year and Q1 2026, resulting in a gross loss for the quarter.
- First-half 2026 total revenue was $6.03 million, slightly down from $6.1 million in the prior year period, though the core energy management platform remained stable at $4.76 million.
- CEO Michael Mo cited four primary headwinds for the quarter: new supply chain lead times for new parts, execution capacity constraints across too many customer programs, management bandwidth consumed by board changes, and the Texas facility not yet being operational.
- +11 more takeaways
Intellicheck Q2 2026 Earnings Call - Diversified Growth Offsets Customer Evaluation Headwinds
Intellicheck delivered a resilient second quarter, posting 7% sequential revenue growth and fifth consecutive quarters of positive adjusted EBITDA, driven by a successful diversification strategy that...
- Q2 revenue rose 7% sequentially and 16% year-over-year to $5.9 million, with SaaS comprising substantially all total revenue.
- Adjusted EBITDA was $1.1 million, marking the fifth consecutive quarter of profitability, supported by $11.8 million in cash and zero debt.
- A major customer (approx. 29% of H1 revenue) is conducting a vendor resiliency evaluation, but management reports the actual volume decline is far less than the client initially projected.
- +7 more takeaways
NextBoat Q2 2026 Earnings Call - Record Revenue and Strategic Pivot to High-Margin F&I
NextBoat delivered a transformative second quarter, posting record revenue of $59.1 million and nearly doubling year-over-year growth. The company returned to adjusted EBITDA profitability, a critical...
- NextBoat reported record Q2 2026 revenue of $59.1 million, an 88.4% increase year-over-year, signaling strong momentum as the company scales its platform.
- Transaction volume surged 138% year-over-year with 255 boats sold, demonstrating the scalability of the NextBoat model and the effectiveness of its AI-driven matching engine.
- The company returned to adjusted EBITDA profitability in Q2, marking a pivotal shift from the investment-heavy public offering phase to a focus on margin expansion and operational efficiency.
- +7 more takeaways
Security National Financial Corporation Q2 2026 Earnings Call - Profitability Surges Despite Revenue Decline and Mortality Headwinds
Security National Financial Corporation delivered a quarter defined by a deliberate pivot from top-line growth to bottom-line efficiency, posting a 7.3% increase in after-tax earnings despite a 6.3% d...
- Consolidated net earnings rose 7.3% in Q2 2026 and 8.1% for the first half, proving that operational discipline is currently outweighing revenue contraction.
- Total revenue fell 6.3% for the quarter and 5% for the first half, confirming that growth has been sacrificed for margin expansion.
- The mortgage segment achieved its first profitable quarter since Q3 2025, with pre-tax income flipping from a $1.67 million loss to a $71,000 profit.
- +7 more takeaways